A Study of Experimental FT-2102 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome (types of blood system cancer)
This study will evaluate the safety, efficacy, PK, and PD of FT-2102 as a single agent or in combination with azacitidine or cytarabine.
- for people ages 18 years and up (full criteria)
- at UC Davis UCLA UCSD
- study startedestimated completion
Acute Myeloid Leukemia Acute Myelogenous Leukemia Myelodysplastic Syndrome AML MDS IDH1 IDH Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Preleukemia Myelodysplastic Syndromes Cytarabine Azacitidine PH1 Dose Escalation & Expansion FT-2102 PH1 Esc. and Exp. FT-2102+Azacitidine PH1 Esc. and Exp. FT-2102+Cytarabine
- accepting new patients
- Start Date
- Completion Date
- Forma Therapeutics, Inc.
- Phase 1/2
- Study Type
- Last Updated